• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    4/26/24 4:31:15 PM ET
    $ACCD
    $AKAN
    $ASLN
    $BGXX
    Business Services
    Consumer Discretionary
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACCD alert in real time by email

    Gainers

    • Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 11.0% to $0.73 during Friday's after-market session. The company's market cap stands at $1.9 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock rose 10.15% to $0.33.
    • Imunon (NASDAQ:IMNN) shares increased by 7.63% to $1.55. The market value of their outstanding shares is at $14.5 million.
    • Accolade (NASDAQ:ACCD) shares increased by 5.83% to $8.35. The market value of their outstanding shares is at $646.3 million. The company's, Q4 earnings came out yesterday.
    • Prime Medicine (NASDAQ:PRME) shares increased by 5.53% to $4.67. The market value of their outstanding shares is at $560.1 million.
    • ASLAN Pharma (NASDAQ:ASLN) stock rose 5.46% to $0.44. The market value of their outstanding shares is at $9.9 million.

    Losers

    • Compass Therapeutics (NASDAQ:CMPX) stock decreased by 8.3% to $1.33 during Friday's after-market session. The market value of their outstanding shares is at $182.9 million.
    • Akanda (NASDAQ:AKAN) shares fell 7.77% to $0.1. The market value of their outstanding shares is at $1.1 million.
    • Portage Biotech (NASDAQ:PRTG) stock declined by 5.37% to $0.24. The market value of their outstanding shares is at $4.7 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares declined by 5.18% to $0.14. The company's market cap stands at $5.5 million.
    • Tevogen Bio Holdings (NASDAQ:TVGN) shares declined by 5.01% to $0.95. The company's market cap stands at $156.3 million.
    • Bright Green (NASDAQ:BGXX) shares fell 4.81% to $0.19. The market value of their outstanding shares is at $36.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACCD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD
    $AKAN
    $ASLN
    $BGXX

    CompanyDatePrice TargetRatingAnalyst
    Prime Medicine Inc.
    $PRME
    3/12/2026$11.00Outperform
    Oppenheimer
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2026Buy → Hold
    D. Boral Capital
    Compass Therapeutics Inc.
    $CMPX
    2/13/2026$15.00Buy
    Craig Hallum
    Compass Therapeutics Inc.
    $CMPX
    1/5/2026Outperform
    William Blair
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Mkt Outperform
    Citizens JMP
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Buy
    Canaccord Genuity
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025Overweight
    Cantor Fitzgerald
    Compass Therapeutics Inc.
    $CMPX
    7/1/2025$9.00Outperform
    Raymond James
    More analyst ratings

    $ACCD
    $AKAN
    $ASLN
    $BGXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Prime Medicine with a new price target

    Oppenheimer initiated coverage of Prime Medicine with a rating of Outperform and set a new price target of $11.00

    3/12/26 8:54:37 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Tevogen Bio from Buy to Hold

    3/4/26 9:36:27 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Compass Therapeutics with a new price target

    Craig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00

    2/13/26 8:35:30 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $AKAN
    $ASLN
    $BGXX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Gv 2021 Gp, L.L.C. bought $4,950,000 worth of shares (1,500,000 units at $3.30) (SEC Form 4)

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    8/5/25 4:07:52 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Nelsen Robert bought $9,999,990 worth of shares (3,030,300 units at $3.30) (SEC Form 4)

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    8/1/25 7:19:58 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $AKAN
    $ASLN
    $BGXX
    SEC Filings

    View All

    SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

    424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    3/25/26 5:10:04 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    3/25/26 5:04:56 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imunon Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Imunon, Inc. (0000749647) (Filer)

    3/23/26 4:16:13 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $AKAN
    $ASLN
    $BGXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

    Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates across 20+ countries, providing global clinical development capabilities WARREN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices. If completed, the transaction would represent a meaningful step in Tevogen's evolution toward a

    3/26/26 12:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akanda Corp. Driving Recurring Revenue Growth: $2 Million Cash Flow Secured Through Fiber Acquisition

    Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its wholly owned subsidiary, First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, are pleased to announce an expansion of its dark fiber network with the addition of approximately 200 kilometres, increasing total network coverage to approximately 900 kilometres across Central Mexico.This milestone is expected to materially advance FTF's strategy to build a scaled, high-margin, cash-flow-generating digital infrastructure platform in what the Company believes is one of Latin America's most attractive and undersupplied connectivity ma

    3/26/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

    WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. As previously disclosed on September 23, 2025, the Company received a notification letter from the Staff of Nasdaq indicating that the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing under Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Requirement"

    3/25/26 2:20:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $AKAN
    $ASLN
    $BGXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Flomenberg Neal sold $6,635 worth of shares (972 units at $6.83), decreasing direct ownership by 1% to 76,940 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    3/17/26 4:29:13 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Reine Allan

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    2/27/26 4:52:39 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Technical Officer Lee Ann L.

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    2/24/26 5:07:31 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $AKAN
    $ASLN
    $BGXX
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

    WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month. Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients. Tevogen continues to prioritize the development of TVGN 489,

    3/11/26 3:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Defining Wellness Centers Names Bill Morrison Chief Financial Officer

    Experienced Healthcare Executive Joins Leadership Team to Support Continued Growth Backed by Fulcrum Equity PartnersJACKSON, Miss., March 9, 2026 /PRNewswire/ -- Defining Wellness Centers (www.definingwellness.com) today announced that veteran healthcare executive Bill Morrison has joined the organization as Chief Financial Officer. Morrison brings more than 25 years of experience helping scale healthcare and behavioral health companies and will oversee the company's financial strategy during a period of continued growth backed by Atlanta-based growth equity firm Fulcrum Equity Partners.

    3/9/26 9:17:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Tevogen Names Leadership Team to Execute Diversified Growth Strategy

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek StobinskiGene

    3/9/26 7:45:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $AKAN
    $ASLN
    $BGXX
    Financials

    Live finance-specific insights

    View All

    IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

    LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1

    3/24/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

    Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive.Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen's lead investor, directors and named executive officers.Company prioritizing long-term stock-based incentive program aligned with company milestones.Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.Company continues to evaluate acquisitions that could generate

    3/13/26 2:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

    WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company's future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors aft

    1/30/26 3:00:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $AKAN
    $ASLN
    $BGXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Prime Medicine Inc.

    SC 13D/A - Prime Medicine, Inc. (0001894562) (Subject)

    11/22/24 5:32:53 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care